장수 진단 시장 규모, 점유율 및 동향 분석 보고서 : 검사 종별, 기술별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Longevity Diagnostics Market Summary

The global longevity diagnostics market size was valued at USD 2.80 billion in 2025 and is projected to reach USD 4.54 billion by 2033, growing at a CAGR of 6.38% from 2026 to 2026. An aging population, the rising prevalence of chronic diseases, and the growing demand for preventive and personalized healthcare drive market growth.

Growth in epigenetic clock technologies, increasing investment in longevity medicine, and expansion of AI-enabled biomarker analytics are further supporting market expansion. The longevity diagnostics market is driven by the increasing aging population and rising burden of chronic diseases, which are accelerating demand for early disease detection, biological age assessment, and preventive health monitoring technologies. According to the World Health Organization (WHO) report published in October 2025, by 2030, one in six people globally will be aged 60 years or older, and the global population aged 60 years or older is projected to reach 2.1 billion by 2050.

Aging populations are increasingly susceptible to cardiovascular diseases, cancer, diabetes, and neurodegenerative disorders, supporting demand for longevity diagnostics solutions. According to U.S. Centers for Disease Control and Prevention (CDC) data updated in April 2026, nearly three in four American adults have at least one chronic condition, while over 90% of adults aged 65 years and older have at least one chronic disease. Furthermore, according to the OECD Health at a Glance report published in February 2025, 82% of primary care users live with at least one chronic condition, 52% live with two or more chronic conditions, and 27% suffer from three or more chronic diseases, increasing demand for AI-enabled biomarker analytics and epigenetic longevity diagnostics.

The longevity diagnostics market is experiencing significant growth driven by rising demand for preventive and personalized healthcare focused on early identification of aging-related health risks and on individualized intervention strategies. Consumers and healthcare providers are increasingly adopting biological age testing, epigenetic clocks, multi-omics profiling, and AI-enabled biomarker analytics to assess physiological aging, disease susceptibility, and age-related disease risk before clinical symptoms develop. Personalized longevity programs integrating genomics, metabolomics, and lifestyle analytics are gaining traction across preventive healthcare settings and specialized longevity clinics, supporting broader adoption of precision longevity diagnostics solutions.

The longevity diagnostics market is experiencing strong growth driven by advancements in epigenetic clock technologies and increasing investment in longevity medicine. Epigenetic clocks utilize DNA methylation patterns to estimate biological age, enabling early assessment of physiological aging, disease susceptibility, and response to preventive interventions. These technologies are increasingly integrated into precision medicine and preventive healthcare programs, supporting demand for longevity diagnostics solutions. Rising investments are accelerating the commercialization of biomarker-based longevity platforms, AI-enabled aging analytics, and multi-omics diagnostics. In March 2025, L'Oreal announced a strategic research partnership with TruDiagnostic to advance epigenetic biomarker research and biological age assessment technologies, supporting the development of personalized longevity diagnostics and preventive health monitoring solutions.

The expansion of AI-enabled biomarker analytics further supports longevity diagnostics market growth by enabling advanced interpretation of genomic, proteomic, and metabolomic data, as well as physiological health data. AI-driven platforms improve biological age prediction, disease risk stratification, and personalized intervention planning, supporting broader adoption of precision longevity diagnostics across preventive healthcare and personalized medicine applications.

Global Longevity Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global longevity diagnostics market report based on test type, technology, end use, and region:

• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Epigenetic Age Testing
• Telomere Length Analysis
• Multi-Omics Profiling
• Proteomics-Based Aging Biomarkers
• Metabolomics Testing
• Microbiome Aging Diagnostics
• Hormone & Metabolic Profiling
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Next-Generation Sequencing (NGS)
• Mass Spectrometry
• AI-Powered Analytics
• Microarray Technology
• Wearable-Integrated Monitoring
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Direct-to-Consumer (DTC)
• Longevity Clinics
• Hospitals & Clinical Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Test Type
  • 1.2.2. Technology
  • 1.2.3. End use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Longevity Diagnostics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Longevity Diagnostics Market: Test Type Business Analysis

• 4.1. Test Type Market Share, 2025 & 2033
• 4.2. Test Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Test Type, 2021 to 2033 (USD Million)
• 4.4. Epigenetic Age Testing
  • 4.4.1. Epigenetic Age Testing Market, 2021 - 2033 (USD Million)
• 4.5. Telomere Length Analysis
  • 4.5.1. Telomere Length Analysis Market, 2021 - 2033 (USD Million)
• 4.6. Multi-Omics Profiling
  • 4.6.1. Multi-Omics Profiling Market, 2021 - 2033 (USD Million)
• 4.7. Proteomics-Based Aging Biomarkers
  • 4.7.1. Proteomics-Based Aging Biomarkers Market, 2021 - 2033 (USD Million)
• 4.8. Metabolomics Testing
  • 4.8.1. Metabolomics Testing Market, 2021 - 2033 (USD Million)
• 4.9. Microbiome Aging Diagnostics
  • 4.9.1. Microbiome Aging Diagnostics Market, 2021 - 2033 (USD Million)
• 4.10. Hormone & Metabolic Profiling
  • 4.10.1. Hormone & Metabolic Profiling Market, 2021 - 2033 (USD Million)

Chapter 5. Longevity Diagnostics Market: Technology Business Analysis

• 5.1. Technology Market Share, 2025 & 2033
• 5.2. Technology Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 5.4. Next-Generation Sequencing (NGS)
  • 5.4.1. Next-Generation Sequencing (NGS) Market, 2021 - 2033 (USD Million)
• 5.5. Mass Spectrometry
  • 5.5.1. Mass Spectrometry Market, 2021 - 2033 (USD Million)
• 5.6. AI-Powered Analytics
  • 5.6.1. AI-Powered Analytics Market, 2021 - 2033 (USD Million)
• 5.7. Microarray Technology
  • 5.7.1. Microarray Technology Market, 2021 - 2033 (USD Million)
• 5.8. Wearable-Integrated Monitoring
  • 5.8.1. Wearable-Integrated Monitoring Market, 2021 - 2033 (USD Million)

Chapter 6. Longevity Diagnostics Market: End use Business Analysis

• 6.1. End use Market Share, 2025 & 2033
• 6.2. End use Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by End use, 2021 to 2033 (USD Million)
• 6.4. Direct-to-Consumer (DTC)
  • 6.4.1. Direct-to-Consumer (DTC) Market, 2021 - 2033 (USD Million)
• 6.5. Longevity Clinics
  • 6.5.1. Longevity Clinics Market, 2021 - 2033 (USD Million)
• 6.6. Hospitals & Clinical Laboratories
  • 6.6.1. Hospitals & Clinical Laboratories Market, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Longevity Diagnostics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America Longevity Diagnostics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. Canada Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. Uk Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Brazil Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. Argentina Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Longevity Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Abbott
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. TruDiagnostic
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Elysium Health
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. GlycanAge.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Tally Health
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Segterra, Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Function Health.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. SiPhox, Inc.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. WellnessFX
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Illumina Inc
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. 23andMe
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives
  • 8.5.12. Nebula Genomics.
    • 8.5.12.1. Overview
    • 8.5.12.2. Financial Performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic Initiatives
  • 8.5.13. NOVOS Labs
    • 8.5.13.1. Overview
    • 8.5.13.2. Financial Performance
    • 8.5.13.3. Product Benchmarking
    • 8.5.13.4. Strategic Initiatives
  • 8.5.14. Altos Labs
    • 8.5.14.1. Overview
    • 8.5.14.2. Financial Performance
    • 8.5.14.3. Product Benchmarking
    • 8.5.14.4. Strategic Initiatives